Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

MBSR y PNL, Lactancia Materna Posparto y Depresión (postpartum)

30 de octubre de 2026 actualizado por: Aysegul Kilicli

el efecto de las aplicaciones de MBSR y PNL sobre la fatiga, la calidad del sueño, la lactancia y la depresión posparto en el período posparto después de una cesárea

The postnatal period is a risky period in which mothers experience regressive and progressive changes and rapid biopsychosocial changes. Since this process affects not only the mother but also the family, mothers are under intense stress due to adaptation to the changes that occur in this period.

Descripción general del estudio

Descripción detallada

The postnatal period is a risky period in which retrogressive and progressive changes and rapid biopsychosocial changes occur in mothers. Since this process affects not only the mother but also the family, mothers are under intense stress due to adaptation to the changes occurring in this period. Studies have reported that the most common physical problems in the early postpartum period after caesarean section are pain in the incision area, difficulty in caring for the baby alone, activity intolerance, fatigue, insomnia, breastfeeding problems (such as nipple or lack of milk), mastitis and abdominal tension/gas. As important as it is to reduce postpartum symptoms after caesarean section, it is also important to support and maintain breastfeeding. However, postpartum symptoms such as pain, fatigue and negative effects of anaesthesia after caesarean section negatively affect the breastfeeding process and lead to a delay in the onset of lactation.

When the literature was examined, no study was found that examined the effects of mindfulness-based stress reduction programme and neurolinguistic programme on fatigue, sleep quality, lactation and depression in the postpartum long term.

Tipo de estudio

Intervencionista

Inscripción (Actual)

90

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Eyalet/Yerleşke
      • Sanliurfa, Eyalet/Yerleşke, Turquía (Türkiye), 63000
        • Şanlıurfa training and research hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

19 años a 35 años (Adulto)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • 19-35 years old
  • caesarean section
  • primiparous
  • breastfeeding women

Exclusion Criteria:

  • women who refused to participate in the research.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Mindfulness-based stress reduction program

MBSR; Mindfulness-based stress reduction program. 8 weeks of practice once a week for 20 minutes each. Mindfulness-based stress reduction practices will be carried out online. Mothers will actively participate.

20 minutes once a week for 8 weeks

Otros nombres:
  • Programa de reducción del estrés basado en mindfulness MBSR
Experimental: Neurolinguistic programming

NLP; Neurolinguistic programming 8 weeks of practice once a week for 20 minutes each. Neurolinguistic programming will be carried out online. Mothers will actively participate.

NLP Neurolinguistic programming, 20 minutes once a week for 8 weeks

Otros nombres:
  • PNL programación neurolingüística
Experimental: control

control; MBSR and NLP applications will not be performed. Mothers will be monitored online every week.

control group, no practice,

Otros nombres:
  • grupo de control

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Visual Analogue Scale for Fatigue (VAS-F)
Periodo de tiempo: before the first application

Visual Analogue Scale for Fatigue (VAS-F), The most positive expression of the fatigue sub-dimension is 0 and the most negative expression is 10, the most negative expression of the energy sub-dimension is 0 and the most positive expression is 10.

before the first application
Visual Analogue Scale for Fatigue (VAS-F)
Periodo de tiempo: Week 4, following the intervention administered on that day

Visual Analogue Scale for Fatigue (VAS-F) The most positive expression of the fatigue sub-dimension is 0 and the most negative expression is 10, the most negative expression of the energy sub-dimension is 0 and the most positive expression is 10.

Week 4, following the intervention administered on that day
Visual Analogue Scale for Fatigue (VAS-F)
Periodo de tiempo: Week 8, following the final intervention

Visual Analogue Scale for Fatigue (VAS-F) The most positive expression of the fatigue sub-dimension is 0 and the most negative expression is 10, the most negative expression of the energy sub-dimension is 0 and the most positive expression is 10.

Week 8, following the final intervention
Pittsburgh Sleep Quality Index (PSQI)
Periodo de tiempo: before the first application

Pittsburgh Sleep Quality Index (PSQI) Each item is evaluated as 0-3 points and the sum of the 7 subcomponents constitutes the PDQI score. The lowest score of the scale is 0 and the highest score is 21. A total PDQI score of ≤5 indicates good sleep and >5 indicates poor sleep.

before the first application
Pittsburgh Sleep Quality Index (PSQI)
Periodo de tiempo: week 4, following the intervention administered on that day

Pittsburgh Sleep Quality Index (PSQI) Each item is evaluated as 0-3 points and the sum of the 7 subcomponents constitutes the PDQI score. The lowest score of the scale is 0 and the highest score is 21. A total PDQI score of ≤5 indicates good sleep and >5 indicates poor sleep.

week 4, following the intervention administered on that day
Pittsburgh Sleep Quality Index (PSQI)
Periodo de tiempo: week 8, , following the final intervention

Pittsburgh Sleep Quality Index (PSQI) Each item is evaluated as 0-3 points and the sum of the 7 subcomponents constitutes the PDQI score. The lowest score of the scale is 0 and the highest score is 21. A total PDQI score of ≤5 indicates good sleep and >5 indicates poor sleep.

week 8, , following the final intervention
Edinburgh Postpartum Depression Scale (EPDS)
Periodo de tiempo: before the first application

Edinburgh Postpartum Depression Scale (EPDS) The scale is a 4-point Likert-type scale consisting of 10 items. Responses consisting of four options are scored between 0 and 3. A minimum of 0 and a maximum of 30 points can be obtained from the scale. The cut-off point of the scale is 13 points and above for women and 10 points and above for men, and above this point indicates the presence of depression.

before the first application
Edinburgh Postpartum Depression Scale (EPDS)
Periodo de tiempo: week 4, following the intervention administered on that day

Edinburgh Postpartum Depression Scale (EPDS) The scale is a 4-point Likert-type scale consisting of 10 items. Responses consisting of four options are scored between 0 and 3. A minimum of 0 and a maximum of 30 points can be obtained from the scale. The cut-off point of the scale is 13 points and above for women and 10 points and above for men, and above this point indicates the presence of depression.

week 4, following the intervention administered on that day
Edinburgh Postpartum Depression Scale (EPDS)
Periodo de tiempo: week 8, following the final intervention

Edinburgh Postpartum Depression Scale (EPDS) The scale is a 4-point Likert-type scale consisting of 10 items. Responses consisting of four options are scored between 0 and 3. A minimum of 0 and a maximum of 30 points can be obtained from the scale. The cut-off point of the scale is 13 points and above for women and 10 points and above for men, and above this point indicates the presence of depression.

week 8, following the final intervention
Breastfeeding Self-Efficacy Scale (BSES)
Periodo de tiempo: before the first application

Breastfeeding Self-Efficacy Scale (BSES) The scale consists of 14 items, five-point Likert type. The items of the scale are evaluated on a scale from '1=never sure' to 5=always sure'. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

before the first application
Breastfeeding Self-Efficacy Scale (BSES)
Periodo de tiempo: week 4, following the intervention administered on that day

Breastfeeding Self-Efficacy Scale (BSES) The scale consists of 14 items, five-point Likert type. The items of the scale are evaluated on a scale from '1=never sure' to 5=always sure'. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

week 4, following the intervention administered on that day
Breastfeeding Self-Efficacy Scale (BSES)
Periodo de tiempo: week 8, following the final intervention

Breastfeeding Self-Efficacy Scale (BSES) The scale consists of 14 items, five-point Likert type. The items of the scale are evaluated on a scale from '1=never sure' to 5=always sure'. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

week 8, following the final intervention
Exclusive breastfeeding status
Periodo de tiempo: before the first application

Exclusive breastfeeding status (yes or no)

before the first application
Exclusive breastfeeding status
Periodo de tiempo: week 4, following the intervention administered on that day

Exclusive breastfeeding status (yes or no)

week 4, following the intervention administered on that day
Exclusive breastfeeding status
Periodo de tiempo: week 8, following the final intervention

Exclusive breastfeeding status (yes or no)

week 8, following the final intervention

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: AYŞEGÜL KILIÇLI, Dr., Muş Alparslan University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

8 de octubre de 2024

Finalización primaria (Actual)

1 de febrero de 2025

Finalización del estudio (Actual)

1 de febrero de 2025

Fechas de registro del estudio

Enviado por primera vez

3 de octubre de 2024

Primero enviado que cumplió con los criterios de control de calidad

3 de octubre de 2024

Publicado por primera vez (Actual)

8 de octubre de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

30 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

All

Marco de tiempo para compartir IPD

8 October 2024 - 30 October 2025

Criterios de acceso compartido de IPD

8 October 2024 - 30 October 2025

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • CÓDIGO_ANALÍTICO
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir